Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMPFD6Y)

Drug Name
Oxindole 94 Drug Info
Synonyms
SB 202190; 152121-30-7; SB202190; SB-202190; FHPI; SB202190 (FHPI); UNII-PVX798P8GI; 4-(4-Fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)-1H-imidazole; CHEBI:79090; 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole; PVX798P8GI; SB 202190, Immobilized; C20H14FN3O; Phenol, 4-[4-(4-fluorophenyl)-5-(4-pyridinyl)-1H-imidazol-2-yl]-; 4-[4-(4-fluorophenyl)-5-(pyridin-4-yl)-1H-imidazol-2-yl]phenol; 4-[5-(4-fluorophenyl)-4-(pyridin-4-yl)-1H-imidazol-2-yl]phenol
Cross-matching ID
PubChem CID
5169
ChEBI ID
CHEMBL278041
CAS Number
CAS 152121-30-7
TTD Drug ID
D0VC0I

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Propanoate metabolism 2.15 0.00e+0 30/34 (88.24%) PCCB;ACAT1;ECHS1;...
DNA replication 2.08 0.00e+0 34/36 (94.44%) FEN1;MCM3;PRIM1;...
Glyoxylate and dicarboxylate metabolism 2.04 0.00e+0 23/30 (76.67%) PCCB;ACAT1;GLUL;...
Valine, leucine and isoleucine degradation 2.00 2.01e-3 42/48 (87.5%) PCCB;ACAT1;ECHS1;...
Steroid biosynthesis 2.00 3.22e-3 19/20 (95%) LSS;TM7SF2;DHCR24;...
Lysine degradation 2.00 2.68e-3 51/63 (80.95%) ACAT1;ECHS1;SMYD3;...
Mismatch repair 1.91 6.90e-3 22/23 (95.65%) MSH2;POLD2;RFC5;...
Homologous recombination 1.78 2.92e-2 35/41 (85.37%) RBBP8;POLD2;BLM;...
One carbon pool by folate 1.77 2.59e-2 15/20 (75%) DHFR;TYMS;MTHFD1;...
Butanoate metabolism 1.75 2.82e-2 23/28 (82.14%) ACAT1;ECHS1;HMGCS1;...
Melanogenesis 1.74 2.78e-2 74/101 (73.27%) ADCY1;PRKCA;GNAI1;...
Citrate cycle (TCA cycle) 1.70 3.55e-2 30/30 (100%) IDH2;SDHA;IDH1;...
Inositol phosphate metabolism 1.70 3.34e-2 66/73 (90.41%) ALDH6A1;MTMR4;IMPA2;...
Fanconi anemia pathway 1.68 3.56e-2 36/54 (66.67%) MLH1;BLM;FANCI;...
Aminoacyl-tRNA biosynthesis 1.67 3.86e-2 15/66 (22.73%) IARS2;TARS2;DARS2;...
MicroRNAs in cancer -1.68 2.65e-2 146/310 (47.1%) CDKN2A;PDGFA;TPM1;...
Hepatitis C -1.70 2.51e-2 139/157 (88.54%) IFIT1;RELA;FAS;...
Fluid shear stress and atherosclerosis -1.70 2.29e-2 123/139 (88.49%) ACVR2A;KLF2;SDC4;...
Primary immunodeficiency -1.72 1.79e-2 33/38 (86.84%) RAG1;CD3D;CD4;...
Estrogen signaling pathway -1.73 1.72e-2 119/137 (86.86%) HSPA1A;ITPR2;KRT20;...
Graft-versus-host disease -1.73 1.79e-2 32/42 (76.19%) FAS;HLA-DPA1;PRF1;...
Herpes simplex virus 1 infection -1.75 1.77e-2 165/498 (33.13%) BCL2L1;CFP;HLA-DRA;...
RIG-I-like receptor signaling pathway -1.77 1.42e-2 64/70 (91.43%) RELA;TBKBP1;CASP8;...
Fat digestion and absorption -1.78 1.32e-2 35/43 (81.4%) GOT2;PLA2G1B;PLA2G2D;...
Kaposi sarcoma-associated herpesvirus infection -1.78 1.33e-2 172/193 (89.12%) CASP8;CXCL3;MAPK3;...
T cell receptor signaling pathway -1.82 9.08e-3 93/104 (89.42%) PPP3CB;PAK1;IL4;...
TGF-beta signaling pathway -1.82 9.56e-3 81/94 (86.17%) CUL1;SMAD6;NBL1;...
Protein digestion and absorption -1.82 1.01e-2 78/103 (75.73%) CELA2B;SLC7A9;COL7A1;...
Vitamin digestion and absorption -1.84 9.97e-3 17/24 (70.83%) APOA4;SCARB1;SLC5A6;...
Hematopoietic cell lineage -1.85 9.84e-3 90/99 (90.91%) GP5;TFRC;CD1C;...
Th1 and Th2 cell differentiation -1.86 8.88e-3 80/92 (86.96%) PPP3CB;JAK2;IL4;...
Proximal tubule bicarbonate reclamation -1.86 9.52e-3 21/23 (91.3%) GLS;PCK1;CA4;...
Allograft rejection -1.88 5.59e-3 32/38 (84.21%) HLA-DRA;IL4;FAS;...
NF-kappa B signaling pathway -1.88 5.05e-3 90/104 (86.54%) RELA;TNFSF11;CSNK2A1;...
C-type lectin receptor signaling pathway -1.91 4.40e-3 93/104 (89.42%) PPP3CB;PAK1;MRAS;...
Epstein-Barr virus infection -1.92 3.63e-3 189/202 (93.56%) RELA;BCL2L11;CD3D;...
Th17 cell differentiation -1.94 4.04e-3 95/107 (88.79%) HLA-DRA;IRF4;FOXP3;...
Cytokine-cytokine receptor interaction -1.99 3.03e-3 246/295 (83.39%) IL2RB;LEPR;TNFSF11;...
Intestinal immune network for IgA production -1.99 3.46e-3 38/48 (79.17%) TNFRSF17;HLA-DRA;IL4;...
Bladder cancer -1.99 4.04e-3 40/41 (97.56%) RPS6KA5;EGFR;MAPK3;...
TNF signaling pathway -2.05 0.00e+0 103/112 (91.96%) EDN1;RELA;FAS;...
Viral protein interaction with cytokine and cytokine re... -2.07 0.00e+0 84/100 (84%) IL20RA;TNFSF14;CCL27;...
Staphylococcus aureus infection -2.10 0.00e+0 72/95 (75.79%) C3;SELP;KRT20;...
IL-17 signaling pathway -2.20 0.00e+0 84/94 (89.36%) ANAPC5;IL4;RELA;...
Mineral absorption -2.84 0.00e+0 48/60 (80%) ATP2B1;SLC30A1;SLC26A3;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 15uM 6H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.04uM - 10uM 6H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.04uM - 10uM 6H, 24H
Fibroblast
Nasopharyngeal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
FIBRNPC CVCL_UK07 Homo sapiens 10uM 6H, 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.04uM - 10uM 6H, 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
1HAEo- CVCL_0128 Homo sapiens 10uM 24H
NL20 CVCL_0461 Homo sapiens 10uM 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 0.04uM - 10uM 6H, 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.04uM - 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 0.04uM - 10uM 6H, 24H
Normal (Fibroblast)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HFL1 CVCL_4295 Homo sapiens 10uM 24H
IMR-90 CVCL_0347 Homo sapiens 10uM 24H
WI-38 CVCL_0579 Homo sapiens 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.04uM - 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.04uM - 10uM 6H, 24H